Overview

A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this randomized, double-blind, active-controlled, flexible dosage, multicenter study is to evaluate the effectiveness and safety of galantamine tablet (16-24mg/day) for 16 weeks in the treatment of mild to moderate Alzheimer's Disease (AD) comparing with Donepezil.

Phase:

Phase 3

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Galantamine